Objectives. To assess US availability and use of measles-mumps-rubella (MMR) vaccination documentation for refugees vaccinated overseas.
T
he United States resettles 70 000 to 110 000 refugees each year.
1 US-bound refugees require an overseas medical examination, 2 but vaccination is not required by regulation before resettlement. 3 Refugees in camps may have received vaccinations recommended by the national immunization programs in their asylum country. 4 However, refugees living in cities may not have received adequate vaccination. Outbreaks of vaccinepreventable diseases with morbidity among refugees have occurred. 5, 6 In December 2012, the Centers for Disease Control and Prevention (CDC) and the US Department of State's Bureau of Population, Refugees, and Migration initiated an overseas vaccination program for US-bound refugees to improve their health and to prevent outbreaks and importation of disease. 7 In this evaluation, we assessed whether vaccination documentation was received by US clinicians at postarrival health assessment and, if so, whether the overseas doses of measles-mumps-rubella (MMR) vaccine were integrated into the ACIP schedule.
METHODS
We approached 14 state refugee health partners to assess records of newly arrived refugees resettling from 5 asylum countriesEthiopia, Kenya, Malaysia, Nepal, and Thailand. The EDN system listed 59 755 refugees in the overseas vaccination program who arrived from these 5 countries in March 2013 through July 2015. We used these records to stratify by asylum country and destination state. Subsequently, we randomly selected an equal proportion of children (aged < 19 years) and adults (aged ‡ 19 years). For these records, respective state refugee health partners were asked whether and how the overseas documentation was received at US refugee clinics-by hard copy in the IOM bag the refugees carry, EDN system, refugee health coordinator, resettlement agency, or other sources.
We linked the domestic vaccination records with the EDN data to determine the type and number of overseas MMR vaccinations. Based on ACIP recommendations, 9 valid doses were defined as a first dose of MMR vaccine administered at 1 year or older and a second dose administered at least 28 days after the first dose. Valid doses and receipt of all 3 components of the vaccine (measles, mumps, and rubella) were counted toward the total of overseas MMR doses given.
Because not all states provided comprehensive US vaccination records from their immunization information systems (IIS), 10 we assessed the vaccination opportunity during the first encounter at US refugee clinics. MMR serological immunity results were assessed if provided.
We calculated the proportion of encounters when overseas documentation was available to the US refugee clinics. Of those, we categorized the visits into (1) appropriately managed (no dose needed, or required MMR and were vaccinated), (2) missed opportunity (required MMR and were not vaccinated), and (3) unnecessary (did not require MMR but were vaccinated). The last group also included persons having contraindications 9 noted on the overseas vaccination documentation, born before 1957, younger than 1 year, or immune based on serology.
RESULTS
We received data for 1118 of 1500 (74.5%) person-records from 12 of 14 (85.7%) statesCalifornia, Colorado, Illinois, Kentucky, Maryland, Minnesota, North Carolina, New York, Ohio, Texas, Utah, and Washington. We were unable to obtain 382 person-records because some refugees were not assessed in the destination states, and some states did not participate because of staffing changes and limited resources to provide data for this assessment. States provided a median of 98 person-records (range = 22-274). Asylum countries were distributed as follows: Ethiopia (n = 208; 18.6%), Kenya (n = 203; 18.2%), Malaysia (n = 211; 18.9%), Nepal (n = 238; 21.3), and Thailand (n = 258; n = 23.1%). Only Illinois provided MMR serology results.
Overall, US refugee clinics received vaccination documentation for 972 (86.9%) of 1118 newly arrived refugees. The overseas vaccination documentation was available at the US refugee clinics and was commonly received via the EDN system or the state refugee health coordinator, who has access to the EDN system for 650 (66.9%) of 972 refugee records. Some vaccination records (n = 424; 43.6%) were obtained from the IOM bag carried by the refugee or provided by the resettlement agency. Of the 972 refugees, 829 (85.3%) were assessed appropriately with respect to MMR vaccination after arrival; 767 (92.9%) of these refugees did not require an MMR dose on arrival and were not vaccinated. Of the 972 refugees, 37 (3.8%) required the MMR vaccine but were not vaccinated, and 106 (10.9%) were vaccinated unnecessarily (Table 1) , of whom 11 were born before 1957 and 1 was pregnant. MMR serology results were provided for 11 refugees; all were immune. Of those, 10 had either received 2 doses overseas or were born before 1957.
DISCUSSION
Our findings indicate that most newly arrived refugees in the participating states had overseas vaccination documentation available at the US refugee clinics, and MMR vaccine was given when needed. Furthermore, many refugees in our assessment did not require an additional dose, because they had received vaccination before entering the United States. This evaluation had limitations. Not all states were equally represented; a median of 98 (range = 22-274) person-records were received. Refugees in this evaluation were not necessarily representative of all refugees. However, refugees from 5 asylum countries with 12 destination states provided important information on domestic vaccination practices in this population. We were not able to assess any additional MMR doses that might have been administered after the first encounter (i.e., beyond the first 90 days after arrival), because we did not have access to those records in the state IIS. Refugee overseas and domestic vaccination information may not have been imported into state IIS.
The CDC's postarrival health guidelines 9 indicate that serological testing is an option when the provider believes that the refugee likely had a previous infection that conferred immunity or received a full vaccine series but did not have the records. Thus, serological testing is not common, and we did not receive MMR serology results from all participating states. Despite successful vaccination efforts, we identified several areas for improvement. Safeguards against administering live vaccine to pregnant women can be strengthened. Eligible refugees who did not receive an MMR dose represent missed opportunities and could potentially affect school enrollment for school-aged children. Most refugees received 2 doses of MMR vaccine overseas and did not need additional vaccination; thus, unnecessary vaccinations are possible when overseas information is not available. Additional outreach to clinicians may improve awareness and reduce unnecessary vaccinations. Finally, additional work is needed in transmitting refugee vaccination information into state IIS so that a broader health community can access important vaccination information.
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